TCGA-GM-A2DB-01A-31R-A18M-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 80
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.270
- GLYCOLYSIS+0.260
- MYC_TARGETS_V2+0.260
- OXIDATIVE_PHOSPHORYLATION+0.260
- ALLOGRAFT_REJECTION+0.250
- SPERMATOGENESIS+0.250
- KRAS_SIGNALING_DN+0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
- FATTY_ACID_METABOLISM+0.200
- XENOBIOTIC_METABOLISM+0.160
Top 10 suppressed
- TGF_BETA_SIGNALING-0.420
- UV_RESPONSE_DN-0.400
- WNT_BETA_CATENIN_SIGNALING-0.390
- MITOTIC_SPINDLE-0.370
- PROTEIN_SECRETION-0.360
- APICAL_SURFACE-0.330
- ANGIOGENESIS-0.320
- ESTROGEN_RESPONSE_EARLY-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- HEDGEHOG_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296848 | — | — | 0.799 |
| 2 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.779 |
| 3 | TCGA-38-4631-01A-01R-1755-07 | — | cohortA4 | 0.762 |
| 4 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.760 |
| 5 | TCGA-69-8255-01A-11R-2287-07 | — | cohortA4 | 0.757 |
| 6 | TCGA-UU-A93S-01A-21R-A41B-07 | — | C | 0.756 |
| 7 | TCGA-64-1677-01A-01R-0946-07 | — | cohortA1 | 0.751 |
| 8 | TCGA-LL-A7SZ-01A-32R-A352-07 | — | B | 0.751 |
| 9 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.749 |
| 10 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.090 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |